MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

Specialty Medicines delivered 15% growth to £3.3 billion, led by Respiratory, Immunology & Inflammation up 10%, Oncology up 42%, and HIV up 12%. CEO Emma Walmsley said the performance reflects “strong ...